NVSEF - Annexon Initiates $100 Million IPO Effort
Quick Take
Annexon (ANNX) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement.
The company is a clinical stage biopharma developing antibodies for treating autoimmune and neurodegenerative diseases.
ANNX is targeting a number of sub-$1 billion markets with a single candidate, ANX005.
When we learn more about the IPO’s pricing assumptions, I’ll provide a final opinion.
Company & Technology
South San Francisco, California-based Annexon was founded to advance a pipeline of antibody treatments for diseases such as Guillain-Barre Syndrome [GBS] and Huntington's Disease.